TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00807885

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: hylenex-facilitated subcutaneous Lactated Ringer's infusion
Description: single subcutaneous 150 U dose of hylenex, followed by subcutaneous infusion of 1000 mL Lactated Ringer's solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: hylenex-facilitated subcutaneous Lactated Ringer's infusion
Description: single subcutaneous 150 U dose of hylenex, followed by subcutaneous infusion of 1000 mL Lactated Ringer's solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: hylenex-facilitated subcutaneous Lactated Ringer's infusion
Description: single subcutaneous 150 U dose of hylenex, followed by subcutaneous infusion of 1000 mL Lactated Ringer's solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: hylenex-facilitated subcutaneous Lactated Ringer's infusion
Description: single subcutaneous 150 U dose of hylenex, followed by subcutaneous infusion of 1000 mL Lactated Ringer's solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: hylenex-facilitated subcutaneous Lactated Ringer's infusion
Description: single subcutaneous 150 U dose of hylenex, followed by subcutaneous infusion of 1000 mL Lactated Ringer's solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: hylenex-facilitated subcutaneous Lactated Ringer's infusion
Description: single subcutaneous 150 U dose of hylenex, followed by subcutaneous infusion of 1000 mL Lactated Ringer's solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: hylenex-facilitated subcutaneous Lactated Ringer's infusion
Description: single subcutaneous 150 U dose of hylenex, followed by subcutaneous infusion of 1000 mL Lactated Ringer's solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: hylenex-facilitated subcutaneous Lactated Ringer's infusion
Description: single subcutaneous 150 U dose of hylenex, followed by subcutaneous infusion of 1000 mL Lactated Ringer's solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: hylenex-facilitated subcutaneous Lactated Ringer's infusion
Description: single subcutaneous 150 U dose of hylenex, followed by subcutaneous infusion of 1000 mL Lactated Ringer's solution
Study: NCT01720576

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Study: NCT04747600

Intervention type: PROCEDURE
Intervention: surgical resection
Description: surgical resection

Intervention type: PROCEDURE
Intervention: surgical resection
Description: surgical resection

Intervention type: PROCEDURE
Intervention: surgical resection
Description: surgical resection

Intervention type: PROCEDURE
Intervention: surgical resection
Description: surgical resection
Study: NCT02724852

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: 0.5 ml of MMR vaccine
Description: Participants in each arm received the same vaccine, a 0.5 ml of MMR vaccine at deltoid region

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 0.5 ml of MMR vaccine
Description: Participants in each arm received the same vaccine, a 0.5 ml of MMR vaccine at deltoid region
Study: NCT02438553

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: OSTNS Neurostimulator
Description: Non-invasive transcutaneous neurostimulation.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo OSTNS Neurostimulator
Description: Placebo non-invasive transcutaneous neurostimulation
Study: NCT03065075

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phenazopyridine
Description: Phenazopyridine 200 mg on morning of postoperative day 1
Study: NCT00150878

Intervention type: OTHER
Group type: OTHER
Intervention: Conditioning therapy
Description: Preparation before allogeneic transplantation

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Conditioning therapy
Description: Preparation before allogeneic transplantation
Study: NCT02469103

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: C2
Description: C2 and colonoscopy will be performed one after another on the same day

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: colonoscopy
Study: NCT00810069

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Duloxetine Hydrochloride
Description: Flexible dose of 60 or 120 mg daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Duloxetine Hydrochloride
Description: Flexible dose of 60 or 120 mg daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Escitalopram
Description: 10 mg in both Early and Delayed Intervention. Flexible dose of 10 to 20 mg daily in Delayed Intervention.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Escitalopram
Description: 10 mg in both Early and Delayed Intervention. Flexible dose of 10 to 20 mg daily in Delayed Intervention.
Study: NCT04691219

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Mulberry leaves powder
Description: Dried powder of mulberry leaves crude extract containing 12 mg of DNJ will be packed in a sealed packet with light and moisture protection. Participants will be instructed to mix 1 packet of the powder with a half glass (approximately 120 mL) of plain water and ingest thrice daily before meals. Additionally, they will be informed to rinse the glass with more water and drink to ensure that all of the powder will be taken.
Study: NCT00561431

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard dose of dialysis
Description: Continuous Venovenous Hemodiafiltration (CVVHDF) effluent dose of 20 ml/kg/hr

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High dose of dialysis
Description: Continuous Venovenous Hemodiafiltration (CVVHDF) effluent rate 35 ml/kg/hr
Study: NCT01682772

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib
Description: Until objective disease progression, unacceptable toxicity or patient withdrawal for whatever reason

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib
Description: Until objective disease progression, unacceptable toxicity or patient withdrawal for whatever reason
Study: NCT03471546

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Palliative Care
Description: Initial consultation and follow-up with a palliative care provider
Study: NCT02423889

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Study: NCT04691219

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Diet control
Description: Participants will be requested for diet control. They will be asked for attending the diet control program, maintaining diet pattern throughout the study period, and recording a 3-day food record. Individual counseling and assessment of compliance will be performed by licensed dietitians every 4 weeks. Diet control is principally based on carbohydrate counting.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Diet control
Description: Participants will be requested for diet control. They will be asked for attending the diet control program, maintaining diet pattern throughout the study period, and recording a 3-day food record. Individual counseling and assessment of compliance will be performed by licensed dietitians every 4 weeks. Diet control is principally based on carbohydrate counting.
Study: NCT01466413

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tropoelastin
Description: Multiple intradermal implants comprising of three treatments, 3 weeks apart, each consisting of 16 injections in total, each 10mm apart in a grid formation over a 3cm x 3cm area of the mid to deep dermis of the medial aspect of the upper arm. Each injection will consist of 20-30ul of product delivered using a 30Gx¼ needle. Each subject will also receive Restylane® Vital Light (control) to the opposite arm following the same treatment regimen and using the same technique. The treatment will be administered on Day 1, 22 and 43.
Study: NCT02862964

Intervention type: OTHER
Intervention: identify L4/L5
Description: * For each participant, a provider will first attempt to identify the L4/L5 space using the traditional technique of palpating the iliac crests to estimate spinal level. The provider will mark this space on the person's back with a single dot from a marking pen. The provider will then use the Accuro to again attempt to identify the L4/L5 interspace and mark this point with two dots.~* The participant will then be taken into the fluoroscopy suite for their scheduled procedure a metal instrument will be laid on the skin at the interspace or interspaces that were marked using the palpation and Accuro techniques. Metal instruments show up on fluoroscopy, but the skin markers will not.~* The anesthesiology attending in the fluoroscopy suite will then confirm the true interspace position of these marks under fluoroscopy performed for the standard of care procedure
Study: NCT04708080

Intervention type: PROCEDURE
Intervention: thoracic epidural analgesia
Description: A thoracic epidural catheter is routinely placed in patients undergoing open heart surgery in our hospital, at least 1 hour before heparin administration during the operation. After standard monitoring (ECG, SpO2, NIBP) is applied to the patients in the operating room, sedoanalgesia is provided with 1-3mg of midazolam and 50-100mcg of fentanyl. Then, by providing sterilization conditions, an epidural catheter is inserted through the T5-T6 interval with Tuohy needle. After confirming the location of the epidural catheter, 25mg / 10ml bupivacaine is administered as a bolus and then 3ml / hour bupivacaine infusion is started from the solution prepared as 3mg / ml and continues until the 48th postoperative hour. On the postoperative 2nd day, the catheter is removed 10-12 hours after LMWH administration and 2-4 hours after UFH, as recommended by the guidelines, paying attention to the anticoagulant administration times applied to the patients.
Study: NCT04144959

Intervention type: DEVICE
Intervention: Indigo Aspiration System
Description: Indigo Aspiration System
Study: NCT01396889

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Echinacea
Description: 0.5ml daily for children 1-2 years old and 2ml daily for children 2-5 years old

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo (0.5ml daily for children 1-2 years old and 2ml daily for children 2-5 years old) for 3 months
Study: NCT03895047

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: tomographic EEG Neurofeedback Training
Description: EEG-Electrodes are placed on the patients head to record the brain activity, EEG-recordings are processed by the standardized Low Resolution Brain Electromagnetic Tomography algorithm (sLORETA) to calculate the frequency spectrum in the auditory cortex, the insula and the anterior cingulate cortex and deliver feedback for the patient

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: tomographic EEG Neurofeedback Training
Description: EEG-Electrodes are placed on the patients head to record the brain activity, EEG-recordings are processed by the standardized Low Resolution Brain Electromagnetic Tomography algorithm (sLORETA) to calculate the frequency spectrum in the auditory cortex, the insula and the anterior cingulate cortex and deliver feedback for the patient

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: tomographic EEG Neurofeedback Training
Description: EEG-Electrodes are placed on the patients head to record the brain activity, EEG-recordings are processed by the standardized Low Resolution Brain Electromagnetic Tomography algorithm (sLORETA) to calculate the frequency spectrum in the auditory cortex, the insula and the anterior cingulate cortex and deliver feedback for the patient

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: tomographic EEG Neurofeedback Training
Description: EEG-Electrodes are placed on the patients head to record the brain activity, EEG-recordings are processed by the standardized Low Resolution Brain Electromagnetic Tomography algorithm (sLORETA) to calculate the frequency spectrum in the auditory cortex, the insula and the anterior cingulate cortex and deliver feedback for the patient
Study: NCT01435759

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antidepressant + SPD489 (Lisdexamfetamine dimesylate) 10 mg
Description: Antidepressant + SPD489 oral, 10 mg, once daily for 8 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antidepressant + SPD489 (Lisdexamfetamine dimesylate) 30 mg
Description: Antidepressant + SPD489 oral, 30 mg, once daily for 8 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antidepressant + SPD489 (Lisdexamfetamine dimesylate) 50 mg
Description: Antidepressant + SPD489 oral, 50 mg, once daily for 8 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antidepressant + SPD489 (Lisdexamfetamine dimesylate) 70 mg
Description: Antidepressant + SPD489 oral, 70 mg, once daily for 8 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Antidepressant + Placebo
Description: oral, once daily for 8 weeks
Study: NCT03752879

Intervention type: PROCEDURE
Intervention: Fundal Pressure
Description: Fundal Pressure to assist the vaginal delivery to shorten the second stage of labor
Study: NCT02541864

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bismuth quadruple therapy
Description: pantoprazole 40 mg bid for 14 days, bismuth subcitrate 120 mg qid for 14 days, tetracycline 500 mg qid for 14 days, metronidazole 250 mg qid for 14 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hybrid therapy
Description: (pantoprazole 40 mg bid for 7 days, amoxicillin 1 g bid for 7 days) followed by (pantoprazole 40 mg bid for 7 days, amoxicillin 1 g bid for 7 days, clarithromycin 500 mg bid for 7 days, and metronidazole 500 mg bid for 7 days)
Study: NCT01526564

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetylcarnitine
Description: Administration of enteric-coated tablets with warm water at half an hour after meals, 1g (2 tablets) each time, 3 times a day, and the interval at or \>4 hours for 8 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 3 t.i.d, two plates per time
Study: NCT02342392

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ranibizumab
Description: Intralesional ranibizumab 0.3 mg/0.03mL injected 1 week before pterygium excision surgery.
Study: NCT03895047

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: tomographic EEG Neurofeedback Training
Description: EEG-Electrodes are placed on the patients head to record the brain activity, EEG-recordings are processed by the standardized Low Resolution Brain Electromagnetic Tomography algorithm (sLORETA) to calculate the frequency spectrum in the auditory cortex, the insula and the anterior cingulate cortex and deliver feedback for the patient

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: tomographic EEG Neurofeedback Training
Description: EEG-Electrodes are placed on the patients head to record the brain activity, EEG-recordings are processed by the standardized Low Resolution Brain Electromagnetic Tomography algorithm (sLORETA) to calculate the frequency spectrum in the auditory cortex, the insula and the anterior cingulate cortex and deliver feedback for the patient
Study: NCT01679392

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine
Description: Unilateral, single shot, ultrasound-guided, transversus abdominis plane block with 20 ml ropivacaine (7.5 mg/ml)
Study: NCT02936843

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Salsalate
Description: 1 gram, 3 times daily by mouth (total of 3 grams daily)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: PLACEBO
Description: Placebo for Salsalate; 2 Tabets, 3 times daily by mouth (total of 3 grams daily)
Study: NCT02190903

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: General endotracheal anesthesia
Description: General Anesthesia~Patients randomized to receive general anesthesia induction of anesthesia with intravenous lidocaine, propofol, fentanyl citrate and vecuronium or cisatracurium, following dosing guidelines defined by protocol. Following tracheal intubation, anesthesia will be maintained with sevoflurane in oxygen and air as defined by protocol. End-tidal gas monitoring (for carbon dioxide and sevoflurane) and maintenance, monitoring, and reversal of neuromuscular blockade will be as per HUP and PPMC routine. Immediate postoperative analgesia will be via IV dilaudid dosed intraoperatively as defined by protocol.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Regional (spinal) Anesthesia
Description: Patients randomized to receive spinal anesthesia will undergo spinal blockade using standard techniques and medications dosed as per protocol, and will include hyperbaric bupivicaine or tetracaine, fentanyl citrate, and epinephrine; algorithms for management of spinal-related hypotension will be defined by protocol. Intraoperative sedation will be achieved via continuous intravenous propofol infusion; supplemental oxygen will be provided by nasal cannula or facemask as needed.
Study: NCT03293524

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: GS010
Description: GS010 is a recombinant adeno-associated viral vector serotype 2 (rAAV2/2) containing the wild-type ND4 gene (rAAV2/2-ND4). GS010 will be administrated via intravitreal injection containing 9E10 viral genomes in 90μL balanced salt solution (BSS) as a single baseline intravitreal injection.

Intervention type: GENETIC
Group type: PLACEBO_COMPARATOR
Intervention: GS010
Description: GS010 is a recombinant adeno-associated viral vector serotype 2 (rAAV2/2) containing the wild-type ND4 gene (rAAV2/2-ND4). GS010 will be administrated via intravitreal injection containing 9E10 viral genomes in 90μL balanced salt solution (BSS) as a single baseline intravitreal injection.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo is a BSS, sterile, apyrogenic solution and used for ocular surgery. The placebo will be administered via intravitreal injection in a volume of 90 μL.
Study: NCT02677870

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: saproterin dihydrochloride
Description: The drug will be given as described in the arm/group descriptions.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: saproterin dihydrochloride
Description: The drug will be given as described in the arm/group descriptions.

Intervention type: OTHER
Group type: OTHER
Intervention: Diet treatment
Description: Patients will maintain a stable, Phe restricted diet (including formula) that is consistent with their diet at the time of enrollment. This will be monitored by food diaries kept for 3 days of each week.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diet treatment
Description: Patients will maintain a stable, Phe restricted diet (including formula) that is consistent with their diet at the time of enrollment. This will be monitored by food diaries kept for 3 days of each week.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Diet treatment
Description: Patients will maintain a stable, Phe restricted diet (including formula) that is consistent with their diet at the time of enrollment. This will be monitored by food diaries kept for 3 days of each week.
Study: NCT00734591

Intervention type: DRUG
Intervention: Exubera
Description: Subjects who had been treated with Exubera in a prior Exubera controlled trial. Following initial use of randomized treatment, physicians and subjects were free to change regimens and dosing based on subject response to assigned treatment (as consistent with routine practice).

Intervention type: OTHER
Intervention: Randomized diabetes therapy
Description: Subjects who had been treated with a comparator (other diabetes treatment including one or more of: subcutaneous insulin, sulfonylureas, biguanides, or thiazolinediones) in a prior Exubera controlled trial.~Following initial use of randomized treatment, physicians and subjects were free to change regimens and dosing based on subject response to assigned treatment (as consistent with routine practice).
Study: NCT02805712

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Verbal Information and Discussion
Description: Intervention patient will receive a outpatient session with a palliative care social worker in the heart failure clinic two weeks post discharge consent focusing on goals of care.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: The control group will receive usual written care material and a palliative care consult if ordered by physician.
Study: NCT03064152

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Rotational Thromboelastometry
Description: ROTEM is a point-of-care coagulation assay.
Study: NCT02492230

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Left Atrial Appendage Closure Device (Watchman)
Description: This device is a self-expanding nickel titanium (nitinol) frame structure with fixation barbs and a permeable polyester fabric cover. The device ranges in diameter from 21 mm to 33 mm to accommodate varying LAA anatomy and size. It will be implanted via a trans-septal approach by use of a catheter based delivery system to seal the ostium of the LAA. The implantation will be guided by fluoroscopy and TEE to verify proper positioning and stability. The dose of warfarin will be adjusted to maintain INR 2.0 - 3.0 for 45 days. If TEE data shows no additional flow in LAA, warfarin will be discontinued: Aspirin dose: 75 mg for all period of study; Clopidogrel dose: 75 mg for 6 months after procedure.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Warfarin
Description: Warfarin dose adjusted to maintain INR 2.0-3.0 for all period of study; Aspirin dose-75mg for 45 days after randomization; Clopidogrel dose-75mg for 6 months after procedure.~All drugs will be started before PCI procedure. Low molecular weight heparins will be used before procedure and will be stopped when INR reach 1.8-2.0.
Study: NCT03839329

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Acceptance and Commitment Training
Description: Acceptance and Commitment Therapy is an acceptance- and mindfulness-based psychotherapy that aims to foster psychological flexibility.
Study: NCT01523145

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Rehabilitation
Description: Integrated Rehabilitation consisting of exercise training (minimum 3 times a week for a total of twelve weeks) and psychoeducational care (4 sessions over 6 months)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control Group
Description: usual follow-up Standard follow-up at the participating heart center
Study: NCT00227539

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pemetrexed disodium

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: adjuvant therapy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: therapeutic conventional surgery

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: fludeoxyglucose F 18
Study: NCT02533934

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Harvoni
Description: Treatment of Hepatitis C with sofosbuvir based HCC therapy
Study: NCT03198858

Intervention type: PROCEDURE
Group type: OTHER
Intervention: CartoUnivu™
Description: Ablation with Carto® 3 System and image integration module = IIM, CartoUnivu™

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Ablation with Carto® 3 System
Description: usual Pulmonary vein isolation Ablation with Carto® 3 System only